FDA Advisers Recommend COVID Vaccines Target XFG Variant
FDA Advisory Panel Votes to Recommend COVID-19 Vaccines Targeting XFG Variant for 2026-2027 Campaign
The U.S. Food and Drug Administration's advisory panel voted on Thursday in favor of recommending that COVID-19 vaccines for the 2026-2027 immunization campaign target the dominant JN.1 lineage XFG variant. Eight out of nine panel members voted in favor, with one abstention.
This recommendation will guide vaccine manufacturers in updating their formulations for the upcoming season. The XFG variant is currently the most prevalent strain in circulation.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
Pfizer, Inc.
Pfizer, through its mRNA vaccine developed with BioNTech, could directly benefit from the demand for a vaccine targeting the XFG variant.
BANCO SANTANDER S.A.
Santander is a bank, so it is not directly affected by vaccine news; indirect effects on economic activity are limited.
Moderna, Inc.
Moderna's mRNA vaccine platform could play a critical role in developing a vaccine against the XFG variant, potentially boosting the company's revenues.
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…